InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid
November 03 2021 - 6:30AM
InMed Pharmaceuticals Inc. (“InMed” or the
“Company”) (Nasdaq: INM), a leader in the manufacturing,
development and commercialization of rare cannabinoids, today
announced that it has filed an international patent application
demonstrating neuroprotection and enhanced neuronal function using
a rare cannabinoid for the potential treatment of neurodegenerative
diseases such as Alzheimer’s Disease, Parkinson’s Disease,
Huntington’s Disease and others.
This Patent Cooperation Treaty (PCT)
application, entitled “Compositions and Methods for Treating
Neuronal Disorders with Cannabinoids”, specifies a rare cannabinoid
that may inhibit or slow the progression of neurodegenerative
diseases by providing neuroprotection in a population of affected
neurons. Furthermore, the PCT application also demonstrates the
subject cannabinoid compound can also be used to promote neurite
outgrowth, signifying the potential to enhance neuronal function.
The rare cannabinoid included in the PCT application is new to
InMed’s portfolio.
“We are very encouraged by this initial data
demonstrating potential for the use of a rare cannabinoid to
improve neuronal function and provide neuroprotection for treating
neurodegenerative disorders including Alzheimer’s disease,
Parkinson’s disease and Huntington’s disease,” stated Dr. Eric Hsu,
Senior Vice President Pre-Clinical Research & Development at
InMed. “This PCT patent application advances our strategy directed
towards researching and developing rare cannabinoids as potential
pharmaceutical therapeutics for diseases with high unmet medical
needs. Expanding our patent portfolio to include, in addition to
cannabinol (CBN), an incremental rare cannabinoid for the potential
treatment of major neurodegeneration indications demonstrates our
continued commitment to our pharmaceutical programs and the
potential of rare cannabinoids in medicine.”
This development further enhances InMed patent
portfolio which currently includes twelve patent families focused
on rare cannabinoids, seven of which address manufacturing
technologies and five focusing on products/formulations. With the
acquisition of BayMedica, the Company has expanded its patent
portfolio to cover additional biosynthetic pathways as well as
semi-synthetic production of both natural rare cannabinoids and
cannabinoid analogs. BayMedica is continuing to develop a growing
library of patentable, new cannabinoid analogs targeting diverse
clinical applications.
The PCT is an international patent law treaty,
which provides a unified procedure for filing patent applications
to protect inventions in each of its member states. There are 153
member countries within the PCT, enabling near-global patent
coverage through successful patent prosecution in the
U.S., Japan, Europe, Canada, Australia, New
Zealand, China, Brazil, Russia, India, as well
as many others.
Learn more about InMed’s Pharmaceutical Programs:
https://www.inmedpharma.com/pharmaceutical/cannabinoids-in-development/
Learn more about InMed’s Cannabinoid Manufacturing Capabilities:
https://www.inmedpharma.com/manufacturing/cannabinoid-manufacturing-capabilities/
About InMed: InMed
Pharmaceuticals is a global leader in the manufacturing,
development and commercialization of rare cannabinoids. Together
with our subsidiary, BayMedica, we have unparalleled cannabinoid
manufacturing capabilities to serve a spectrum of consumer markets,
including pharmaceutical and health and wellness. We are a
clinical-stage company developing a pipeline of rare cannabinoid
therapeutics and dedicated to delivering new treatment alternatives
to patients that may benefit from cannabinoid-based pharmaceutical
drugs. For more information, visit www.inmedpharma.com.
Investor Contact: Colin ClancySenior Director,
Investor RelationsT: +1 604 416 0999E: cclancy@inmedpharma.com
Edison Group:Joe Green/Laine
YonkerT: +1.646.653.7030/+1.646.653.7035E:
jgreen@edisongroup.com / lyonker@edisongroup.com
Cautionary Note Regarding
Forward-Looking Information:This news release contains
"forward-looking information" and "forward-looking statements"
(collectively, "forward-looking information") within the meaning of
applicable securities laws. Forward-looking statements are
frequently, but not always, identified by words such as “expects”,
“anticipates”, “believes”, “intends”, “potential”, “possible”,
“would” and similar expressions. Such statements, based as they are
on current expectations of management, inherently involve numerous
risks, uncertainties and assumptions, known and unknown, many of
which are beyond our control. Forward-looking information is based
on management's current expectations and beliefs and is subject to
a number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about: researching and developing rare
cannabinoids as potential pharmaceutical therapeutics for diseases
with high unmet medical needs; that an identified rare cannabinoid
may inhibit or slow the progression of neurodegenerative diseases
such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s
Disease and others; that an identified rare cannabinoid may promote
neurite outgrowth and improve neuronal function; and continuing to
develop a growing library of patentable, new cannabinoid analogs
targeting diverse clinical applications.
With respect to the forward-looking information
contained in this news release, InMed has made numerous assumptions
regarding, among other things: continued economic, regulatory and
market stability; delivering new therapeutic alternatives to
patients that may benefit from cannabinoid-based pharmaceutical
drugs; and developing a pipeline of cannabinoid-based
pharmaceutical drug candidates. While InMed considers these
assumptions to be reasonable, these assumptions are inherently
subject to significant business, economic, competitive, market and
social uncertainties and contingencies.
Additionally, there are known and unknown risk
factors which could cause InMed's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking information contained herein. Known risk factors
include, among others: regulatory filings may not be filed or
approved on a timely basis, or at all. A more complete discussion
of the risks and uncertainties facing InMed’s stand-alone business
is disclosed in InMed’s Annual Report on Form 10-K and other
filings with the Security and Exchange Commission on
www.sec.gov.
All forward-looking information herein is
qualified in its entirety by this cautionary statement, and InMed
disclaims any obligation to revise or update any such
forward-looking information or to publicly announce the result of
any revisions to any of the forward-looking information contained
herein to reflect future results, events or developments, except as
required by law.
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Mar 2024 to Apr 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Apr 2023 to Apr 2024